Huib N. Caron
Affiliations: | University of Amsterdam, Amsterdam, Netherlands |
Area:
Pediatric oncologyWebsite:
https://www.amc.nl/web/Onderwijs/AIOS/Differentiatiestages/Aanbod-van-A-tot-Z/Oncologie-I-en-II-Kinderen.htmGoogle:
"Hubertus Nicolaas (Huib) Caron"Bio:
Prof. dr. H.N. Caron at the Album Academicum of the University of Amsterdam
Mean distance: 24.43 | S | N | B | C | P |
Parents
Sign in to add mentor| Paul Antoine Voûte | grad student | 1995 | Amsterdam | |
| Andries Westerveld | grad student | 1995 | Amsterdam (Chemistry Tree) | |
| (Chromosome 1P in neuroblastoma: suppressors and prognosis) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bate-Eya LT, Gierman HJ, Ebus ME, et al. (2017) Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. European Journal of Cancer (Oxford, England : 1990). 75: 63-72 |
| Bate-Eya LT, den Hartog IJ, van der Ploeg I, et al. (2016) High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget |
| van Wezel EM, Decarolis B, Stutterheim J, et al. (2016) Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. European Journal of Cancer (Oxford, England : 1990). 54: 149-158 |
| Bate-Eya LT, Hartog IJMd, Ploeg Ivd, et al. (2016) Abstract B09: MCL-1 inhibition improves ABT199 efficacy for BCL-2-dependent neuroblastoma Cancer Research. 76 |
| Eleveld TF, Schild L, Ebus ME, et al. (2016) Abstract A31: Activation of the RAS-MAPK pathway in primary neuroblastoma tumors is associated with poor prognosis Cancer Research. 76 |
| Dolman ME, Poon E, Ebus ME, et al. (2015) Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Eleveld TF, Oldridge DA, Bernard V, et al. (2015) Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics |
| Kraal KC, Tytgat GA, van Eck-Smit BL, et al. (2015) Upfront treatment of high-risk neuroblastoma with a combination of (131) I-MIBG and Topotecan. Pediatric Blood & Cancer. 62: 1886-91 |
| Ariës IM, van den Dungen RE, Koudijs MJ, et al. (2015) Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. Haematologica. 100: e132-6 |
| van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, et al. (2015) Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. The Journal of Molecular Diagnostics : Jmd. 17: 43-52 |